摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

木防己苦毒宁 | 17617-45-7

中文名称
木防己苦毒宁
中文别名
汉中防己提取物
英文名称
picrotoxinin
英文别名
picrotoxin;(1R,3R,5S,8S,9R,12S,13R,14R)-1-hydroxy-13-methyl-14-prop-1-en-2-yl-4,7,10-trioxapentacyclo[6.4.1.19,12.03,5.05,13]tetradecane-6,11-dione
木防己苦毒宁化学式
CAS
17617-45-7
化学式
C15H16O6
mdl
——
分子量
292.288
InChiKey
PIMZUZSSNYHVCU-YKWPQBAZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    203-205°C
  • 比旋光度:
    D17 +4.4° (c = 4.28 in abs alc), +3.49° (c = 7.57 in acetone)
  • 沸点:
    354.22°C (rough estimate)
  • 密度:
    1.2207 (rough estimate)
  • LogP:
    -0.130 (est)
  • 碰撞截面:
    168.7 Ų [M+Na]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    85.4
  • 氢给体数:
    1
  • 氢受体数:
    6

安全信息

  • 危险等级:
    6.1(a)
  • 危险品标志:
    T+
  • 安全说明:
    S13,S20,S28,S36/37,S45
  • 危险类别码:
    R25,R28
  • WGK Germany:
    3
  • 危险品运输编号:
    UN 3172
  • RTECS号:
    PC5150000
  • 包装等级:
    I
  • 危险类别:
    6.1(a)

SDS

SDS:66831635e712f155c6940a4098635b33
查看

制备方法与用途

生物活性方面,吡咯托品是一种有效的惊厥药物,它能够阻断氯通道。作为一种非竞争性GABAA受体拮抗剂,吡咯托品会负向调节GABA对GABAA受体的激活作用。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    木防己苦毒宁 在 palladium on activated charcoal 、 乙酸乙酯 作用下, 生成 β-Dihydropicrotoxinin
    参考文献:
    名称:
    63.微毒素。第二部分 吡咯烷酮和吡咯烷醇
    摘要:
    DOI:
    10.1039/jr9360000288
  • 作为产物:
    描述:
    Picrotoxin 在 作用下, 生成 木防己苦毒宁
    参考文献:
    名称:
    Horrmann, Chemische Berichte, 1912, vol. 45, p. 2090,2092
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] CANNABINOID COMPOUNDS<br/>[FR] COMPOSÉS CANNABINOÏDES
    申请人:BOWDEN MATTHEW JAMES
    公开号:WO2014167530A1
    公开(公告)日:2014-10-16
    The present invention relates generally to cannabinoid compounds, more particularly indole and indazole compounds of formula I and la and pharmaceutical compositions comprising the compounds. The compounds are useful treating pain, treating nausea and/or emesis, stimulating appetite, inducing a euphoric effect, inducing relaxation, and inducing a positive mood change, in particular for treating pain, treating nausea and/or emesis, and stimulating appetite.
    本发明一般涉及大麻素化合物,更具体地涉及公式I和Ia的吲哚和吲唑化合物以及包含这些化合物的药物组合物。这些化合物可用于治疗疼痛、治疗恶心和/或呕吐、刺激食欲、诱发愉快效果、诱发放松以及诱发积极情绪变化,特别是用于治疗疼痛、治疗恶心和/或呕吐以及刺激食欲。
  • Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steroids
    申请人:Washington University
    公开号:US20040242549A1
    公开(公告)日:2004-12-02
    Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the &agr;-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity.
    新型戊环甾体和戊环D-同系甾体,包括:(i) 分别为四环甾体环系或四环D-同系甾体环系;(ii) 一个C(3)取代基,选自以下组:(a) 在α-构型中的羟基或羧基,和(b) 硫酸根或其他带负电的基团;以及(iii) 一个融合的第五环,该融合的第五环包含一个氢键受体,且在(a) 戊环甾体的情况下为C(13)和C(17)碳原子,或在(b) 戊环D-同系甾体的情况下为C(13)和C(17a)碳原子,可用作麻醉剂和在治疗与GABA功能和活性相关的疾病中有用。
  • [EN] SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS<br/>[FR] UTILISATION DE DÉRIVÉS DE THIOHYDANTOIN SUBSTITUÉ EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'ANDROGÈNES
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2017123542A1
    公开(公告)日:2017-07-20
    Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: Formula (I) wherein R1 and G are defined herein.
    揭示了用于治疗受到一个或多个雄激素受体拮抗影响的疾病的化合物、组合物和方法。这些化合物由以下的化学式(I)表示:化学式(I)其中R1和G在此处定义。
  • Hydromethylation of Unactivated Olefins
    作者:Hai T. Dao、Chao Li、Quentin Michaudel、Brad D. Maxwell、Phil S. Baran
    DOI:10.1021/jacs.5b05144
    日期:2015.7.1
    problem of olefin hydromethylation is presented. This highly chemoselective method can tolerate labile and reactive chemical functionalities and uses a simple set of reagents. An array of olefins, including mono-, di-, and trisubstituted olefins, are all smoothly hydromethylated. This mild protocol can be used to simplify the synthesis of a specific target or to directly “edit” complex natural products
    提出了烯烃氢甲基化的经典未解决问题的解决方案。这种高度化学选择性的方法可以耐受不稳定和反应性的化学官能团,并使用一组简单的试剂。一系列烯烃,包括单、二和三取代的烯烃,都可以顺利地进行氢甲基化。这种温和的协议可用于简化特定目标的合成或直接“编辑”复杂的天然产物和其他先进材料。该方法还适用于放射性和稳定标记甲基的简单安装。
  • METHODS AND COMPOSITIONS FOR TREATING INFECTION
    申请人:UNIVERSITY OF ROCHESTER
    公开号:US20150238473A1
    公开(公告)日:2015-08-27
    Provided herein are compositions and methods for treating or preventing infection.
    本文提供了用于治疗或预防感染的组合物和方法。
查看更多

同类化合物

马桑宁内酯 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 5-hydroxymethyl-3-methyl-2H-furo[2,3-c]pyran-2-one 5-fluoromethyl-2H-furo[2,3-c]pyran-2-one 5-chloromethyl-2H-furo[2,3-c]pyran-2-one 10,11-Anhydro-5-deoxy-1,2-O-isopropylidene-9-O-(methoxymethyl)-β-L-xylo-L-ido-7-undeculofuranose-(1,4)-pyranose-(7,3) 3,7-dimethyl-2H-furo[2,3-c]pyran-2-one 4R-(3αβ,3aβ,4β,5α,6β,7aβ)hexahydro-2,2-dimethyl-4,5-bis(phenylmethoxy)-6-[(phenylmethoxy)methyl]4H-furo[2,3-b]pyran-3-ol 10,10-dimethyl-5-(methylsulfanyl)-10,11-dihydro-8H-pyrano[4',3':4,5]furo[3,2-e]tetrazolo[1,5-c]pyrimidine (R)-3-((2R,3R,5aR,7R,9aS)-3-hydroxyhexahydro-2H-2,5a-methanopyrano[3,2-e][1,4]dioxepin-7-yl)-2-methylpropanenitrile 13-methyl-8,10,12-trioxapentacyclo[5.5.2.02,6.O3,11.05,9]-13-tetradecene 2,3,4,4a,7,8-Hexahydro-6H-2-(acetoxymethyl)-3,4-diacetoxy-1,9-dioxacyclohexainden-5-one 2,3,4,4a,7,8-Hexahydro-6H-2-methoxy-1,9-dioxacyclohexainden-5-one (-)-3a-methyl-3a,4-dihydro-1H,3H-furo[3,4-c]pyran-6,6,7-tricarboxylic acid 6,6-diethyl ester 7-methyl ester (+)-8-epi-altholactone 4-(perfluorophenyl)-3-phenylhexahydro-1H-furo[3,4-c]pyran [(2R,11S,12R,14R,15R,17R,19S)-19-tert-butyldiphenylsiloxymethyl-15-methyl-13,18-dioxadispiro(2H-3,6-dihydropyran-6,5'-oxolane-2',3''-bicyclo[4.3.0]nonane)-2-yl]phenylmethoxymethane (3aS,5S,9bS)-5-methyl-3,3a-dihydro-5H-furo[3,2-c]isochromene-2,6,9-(9bH)-trione (3aR,5R,7aR)-5-(2-hydroxypropan-2-yl)-7a-methylhexahydro-2H-furo[3,2-b]pyran-2-one 2,2,3b-trimethyl-7-vinyl-3a,5,7a,8a-tetrahydro-3bH-1,3,4,8-tetracyclopenta[a]indene ethyl 4-oxo-3-phenyl-3,3a,4,6-tetrahydro-1H-furo[3,4-c]pyran-3a-carboxylate methyl (2R,2aR,4aS,7aS,7bS)-2-methoxy-6-methyl-4-oxo-5-pentyl-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxacyclopenta[cd]indene-7a-carboxylate 4-nonyl-3-phenylhexahydro-1H-furo[3,4-c]pyran 3'-(4-methoxyphenyl)-7a'-methyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 3',7a'-dimethyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 2-(methylsulfanyl)-5,6-dihydro-4H-furo[2,3-b]pyran 1,1-(3-dimethylamino-3-phenylpentamethylen)-3,4-dihydro-1H-2,9-dioxafluoren 7-cyclopropyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one (4'R)-6-O-(4-cyanophenyl)-1,2,3,4-tetradeoxy-4'-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononyl)-2',3',4',5'-tetrahydro-α-D-erythro-hexopyranoso[1,2-b]furan 2,2,3,6-tetramethyl-2,3-dihydro-4H-furo[2,3-b]pyran-4-one (1aR,4aS,5R)-7-carboethoxy-5-methylethyl-tetrahydrofurano[2,3-b]3,4-dihydro-2H-pyran (3aS,4S,7aR)-ethyl 4-methyl-3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran-6-carboxylate